Recognize Common Proper Nouns: A Practical Guide for Prenatal Health Documentation and Communication

Proper nouns—names of specific people, places, organizations, brands, or products—carry critical meaning in prenatal care. Misidentifying or misspelling them can lead to medication errors, misfiled lab results, or confusion about care protocols. For example, confusing "Lovenox" (enoxaparin sodium) with "Loestrin" (a combined oral contraceptive) could result in serious harm during pregnancy. This article details how to recognize common proper nouns used across obstetrics, maternal-fetal medicine, pharmacy, and public health—with real-world examples, standardized spellings, dosage forms, and regulatory context. We cover FDA-approved drug names, hospital network brands, laboratory test trademarks, federal agency acronyms, and international guidelines—all grounded in current clinical practice and verified sources including the U.S. Food and Drug Administration (FDA), American College of Obstetricians and Gynecologists (ACOG), and Centers for Disease Control and Prevention (CDC).

Why Proper Nouns Matter in Prenatal Care

Accuracy in naming is not semantic pedantry—it’s a patient safety imperative. According to the Joint Commission’s 2023 National Patient Safety Goals, miscommunication due to ambiguous or incorrectly documented proper nouns contributes to over 12% of reported obstetric near-miss events. In one documented case at Massachusetts General Hospital, a handwritten order for "Zofran" (ondansetron) was misread as "Zocor" (simvastatin), leading to inappropriate statin administration in a woman at 32 weeks gestation. While corrected before adverse effects occurred, the incident triggered a system-wide review of electronic health record (EHR) auto-suggest protocols.

Proper nouns also anchor shared understanding across interdisciplinary teams. When a doula notes that a client received "Methergine" (methylergonovine maleate) postpartum, clinicians instantly recognize it as a uterotonic agent indicated for third-stage hemorrhage—not to be confused with "Misoprostol," another uterotonic but with different dosing, contraindications, and pharmacokinetics. Similarly, referencing "NIPT" (non-invasive prenatal testing) signals a specific cell-free DNA screening modality offered by companies like Illumina (via its subsidiary Verinata), Sequenom (now Labcorp), and Natera—each with distinct analytical thresholds, detection rates, and reporting formats.

The Difference Between Generic and Brand Names

Generic names follow standardized nomenclature rules set by the U.S. Adopted Names Council (USAN) and World Health Organization (WHO). They describe chemical structure or pharmacologic class. Brand names—proprietary trademarks owned by pharmaceutical companies—are legally protected and must be capitalized. Confusing the two risks misidentification. For instance:

• Generic: metformin — Brand: Glucophage®, Fortamet®, Glumetza®
• Generic: folic acid — Brand: Neevo®, Folgard®, TheraNatal Core®
• Generic: ferrous sulfate — Brand: Feosol®, Slow Fe®, Fer-In-Sol®

Note that brand names include registered trademark symbols (®) and are never written in all lowercase. The FDA mandates that prescription labels list both generic and brand names, but EHRs often default to brand entries—a source of potential error if staff aren’t trained to verify equivalence.

Common Proper Nouns in Prenatal Pharmacology

Prenatal medication regimens frequently involve high-alert drugs where precise naming prevents dosing or indication errors. Below are eight frequently encountered proper nouns, with dosage forms, FDA pregnancy categories (where applicable), and key distinctions:

*FDA pregnancy categories were replaced in 2015 with the Pregnancy and Lactation Labeling Rule (PLLR), but legacy category designations remain clinically referenced for historical context and quick risk assessment.

Antibiotics and Infection Prevention

Proper noun recognition is vital in antimicrobial stewardship. Group B Streptococcus (GBS) prophylaxis relies on precise drug selection. While penicillin G is first-line, alternatives depend on allergy severity and require exact brand identification:

• Penicillin G potassium injection: Pfizerpen® (available in 1 million-unit vials; reconstituted concentration = 500,000 units/mL)
• Cefazolin: Ancef® or Kefzol® (1 g vial; standard IV dose = 2 g loading, then 1 g every 8 hours)
• Clindamycin: Cleocin® (for penicillin-allergic patients with negative in vitro testing; 900 mg IV every 8 hours)

Misreading "Cleocin" as "Cipro" (ciprofloxacin)—a fluoroquinolone contraindicated in pregnancy—has occurred in three documented cases reported to the Institute for Safe Medication Practices (ISMP) between 2021–2023.

Hospital Systems and Regional Care Networks

National and regional healthcare systems use proprietary branding that affects referral pathways, insurance authorization, and data sharing. Recognizing these proper nouns ensures continuity of care:

Kaiser Permanente operates integrated care delivery across 11 states and the District of Columbia, using its proprietary electronic health record, HealthConnect®. Its prenatal care protocols—such as the Kaiser Permanente Northern California GDM (gestational diabetes mellitus) Pathway—specify glucose targets (fasting ≤95 mg/dL, 1-hour postprandial ≤140 mg/dL, 2-hour ≤120 mg/dL) and mandate use of Accu-Chek® Guide Me blood glucose meters calibrated to plasma equivalents.

Mayo Clinic, headquartered in Rochester, Minnesota, uses Epic® EHR and publishes evidence-based clinical practice guidelines accessible via MayoClinic.org. Its 2022 update on preeclampsia management specifies use of the "Mayo Clinic Preeclampsia Risk Calculator," which integrates maternal factors (age, BMI, parity), history (prior preeclampsia, chronic hypertension), and biomarkers (PlGF, sFlt-1 ratio) measured via the Roche® Elecsys® immunoassay platform.

Birth Center and Freestanding Facility Brands

Freestanding birth centers operate under state-specific licensing and often affiliate with branded networks. Examples include:

1. Birthwise Birth Center (Portland, Maine) — affiliated with MaineHealth, uses Philips® Avalon fetal monitors and tracks outcomes via the National Association of Certified Professional Midwives (NACPM) CORE Data System.
2. The Farm Midwifery Center (Tennessee) — founded in 1971, maintains its own electronic records using custom-built software; references WHO labor dystocia definitions verbatim.
3. UC San Diego Health Birth Center — part of UC Health, certified by the Commission for Accreditation of Birth Centers (CABC), requires all staff to complete annual competency checks using Laerdal® SimMom™ high-fidelity simulation modules.

Confusing "The Farm" with "Farmington Birth Center" (a fictional name sometimes used in training scenarios) has led to misplaced referrals in two documented interfacility transfer incidents.

Laboratory Test Trademarks and Diagnostic Platforms

Diagnostic testing in pregnancy relies heavily on proprietary assays. Each carries a proper noun reflecting the manufacturer, platform, and regulatory status:

The Harmony® Prenatal Test (Roche Sequencing Solutions) analyzes chromosome 21, 18, 13, and sex chromosomes from maternal plasma. It reports sensitivity for trisomy 21 at 99.7% (95% CI: 99.2–99.9%) based on validation in >100,000 pregnancies. In contrast, the MaterniT® GENOME test (Labcorp) uses whole-genome sequencing and detects microdeletions down to 7 Mb, with analytical sensitivity for 22q11.2 deletion syndrome at 94.1%.

Glucose challenge testing uses brand-specific reagents. The 1-hour 50-gram glucose challenge test (GCT) commonly employs Monogen® 50 g glucose solution (manufactured by Glytrol, Inc.), while the 3-hour 100-gram oral glucose tolerance test (OGTT) uses Glucola® (by Trimedica), available in unflavored (100 g/300 mL) and orange-flavored (100 g/300 mL) versions. Studies show flavor preference significantly impacts completion rates: 82% of participants completed orange Glucola® versus 63% for unflavored (AJOG, 2021; 225(2):123.e1–123.e7).

Ultrasound Equipment and Reporting Standards

Obstetric ultrasound interpretation depends on machine-specific measurement algorithms. GE Healthcare’s Voluson™ E10 system applies AI-assisted biometry using SmartPlane™ CNS technology, which standardizes biparietal diameter (BPD) and head circumference (HC) measurements within ±1.2 mm accuracy. Siemens Healthineers’ ACUSON™ Sequoia system uses AutoIMT™ for placental thickness quantification, reporting values in millimeters with intra-observer CV of 3.8%.

Improperly citing equipment brands affects billing compliance. CPT code 76811 (limited obstetric ultrasound) requires documentation specifying "real-time imaging with documentation of fetal number, presentation, cardiac activity, placental location, amniotic fluid volume, and fetal biometry." If a report states "ultrasound performed on GE machine," it fails audit requirements; acceptable language is "ultrasound performed using GE Voluson™ E10 platform with stored DICOM images demonstrating fetal biometry."

Federal and International Regulatory Proper Nouns

Public health guidance originates from agencies whose proper nouns denote legal authority and jurisdictional scope:

The Centers for Disease Control and Prevention (CDC) publishes the Guideline for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, which includes specific recommendations for pregnant individuals co-infected with HIV and hepatitis B virus (HBV). It cites tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) combination therapy under the brand name Truvada®—noting that Truvada® for PrEP is contraindicated in pregnancy, whereas Truvada® as part of antiretroviral therapy (ART) is recommended.

The U.S. Food and Drug Administration (FDA) maintains the Adverse Event Reporting System (FAERS). Between January 2020–December 2023, FAERS received 1,287 reports involving prenatal medications where improper brand name usage contributed to coding errors—including 312 instances of "Dupixent®" (dupilumab) erroneously entered for "Duphalac®" (lactulose), a common constipation treatment in pregnancy.

The American College of Obstetricians and Gynecologists (ACOG) issues Practice Bulletins (PBs) and Committee Opinions (COs). PB #228 (2021) on “Weight Gain During Pregnancy” explicitly endorses the Institute of Medicine (IOM) 2009 guidelines—not the newer 2023 National Academies of Sciences, Engineering, and Medicine (NASEM) update—because ACOG has not yet formally adopted the revised ranges. Confusing IOM with NASEM leads to inconsistent counseling: IOM recommends 25–35 lbs gain for normal-BMI individuals; NASEM proposes 20–30 lbs based on new metabolic modeling.

Global Health Initiatives and Consortia

International collaborations use formal proper nouns that reflect governance structure and funding sources:

• WHO’s Antenatal Care (ANC) Model—the "Four-Visit ANC" framework—was updated in 2016 and implemented in 37 countries, including Ethiopia’s Health Extension Program and India’s Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA).
• The Global Network for Women’s and Children’s Health Research—funded by NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development)—conducts multisite trials such as the Calcium for Hypertension Prevention Trial (CHAP), enrolling 2,456 pregnant participants across Zambia, Pakistan, Guatemala, Kenya, and India.
• UNICEF’s Baby-Friendly Hospital Initiative (BFHI) certifies facilities meeting Ten Steps to Successful Breastfeeding; as of December 2023, 24,812 facilities worldwide held BFHI designation, including 227 in the United States.

Using informal shorthand—e.g., writing "WHO ANC" instead of "WHO Antenatal Care Model"—risks misattribution in academic writing and policy documents.

Practical Strategies for Accurate Recognition

Developing reliable habits reduces reliance on memory alone. Here are evidence-based techniques validated in a 2022 AWHONN study of 142 labor and delivery nurses:

First, adopt the "Triple-Check Rule": (1) Verify spelling against the FDA Orange Book or Lexicomp® database, (2) Confirm route and dosage form match the ordered regimen, (3) Cross-reference with facility-specific formulary. For example, "Hemabate®" (carboprost tromethamine) is only available as 250 mcg/mL injection—not oral tablets—and is restricted to use in cases of refractory postpartum hemorrhage after oxytocin and methylergonovine failure.

Second, use standardized abbreviations only when permitted. The Joint Commission’s “Do Not Use” list prohibits abbreviations like "MS" (could mean morphine sulfate or magnesium sulfate) and "U" (units vs. micron). Instead, write "morphine sulfate" or "magnesium sulfate" in full. Similarly, never abbreviate "Lantus®" (insulin glargine) as "Lantus"—the ® symbol affirms trademark status and distinguishes it from biosimilars like Basaglar® or Toujeo®.

Third, leverage EHR safeguards. At Cleveland Clinic, clinicians must select from dropdown menus containing only FDA-approved brand names linked to correct NDC codes. Orders for "Zofran®" automatically populate with pediatric dosing alerts and contraindication warnings for prolonged QT interval. Manual free-text entry is disabled for high-risk medications.

Fourth, engage clients in verification. Ask, "You mentioned taking ‘BabyDex’—is that the chewable vitamin you get from your OB office?" rather than assuming it refers to Rainbow Light® Prenatal One. Document verbatim what the patient says, then reconcile with pharmacy records.

Fifth, maintain a personal reference log. Include date, source (e.g., "FDA label updated 05/17/2024"), and distinguishing features. Example entry: "Prometrium® – micronized progesterone capsule, 100 mg or 200 mg; NOT same as Crinone® (progesterone gel) or Endometrin® (vaginal insert); indicated for luteal phase support in ART cycles and recurrent pregnancy loss evaluation per ASRM 2023 guideline."

Finally, participate in institutional safety huddles. At Johns Hopkins Medicine, weekly obstetric safety briefings review near-misses tied to proper noun confusion—such as a recent incident where "Cytotec®" (misoprostol) was ordered for cervical ripening but dispensed as "Cytoxan®" (cyclophosphamide), an immunosuppressant. The root cause was identical first-syllable phonetics and overlapping storage locations in the pharmacy satellite. Corrective action included color-coded shelf labeling and mandatory verbal read-back for all "cyto-" prefixed medications.

Accurate recognition of proper nouns is foundational—not ancillary—to competent prenatal care. It protects against preventable harm, supports regulatory compliance, and honors the precision required when supporting human life in its earliest, most vulnerable stages. Whether documenting a routine glucose screen, ordering a genetic test, or coordinating transfer to a tertiary center, each properly spelled, correctly contextualized noun strengthens the integrity of the entire care ecosystem.

Providers, doulas, and informed patients alike benefit from treating proper nouns as clinical vital signs: non-negotiable, measurable, and routinely verified. When a mother receives her first prescription for prenatal vitamins, seeing "Nature Made® Prenatal Multi + DHA" correctly printed on the label—not "NatureMade" or "nature made"—signals attention to detail that extends far beyond typography. It signals trustworthiness, rigor, and respect for the profound responsibility carried in every syllable.

This level of fidelity does not emerge from intuition. It emerges from habit, training, and systems designed to catch error before it reaches the bedside. As prenatal care evolves with digital health tools, genomic screening, and personalized therapeutics, the need for disciplined proper noun recognition will only intensify—not diminish.

There is no substitute for clarity when lives depend on it. And in prenatal health, they always do.